Teva Pharmaceutical Industries Ltd (ADR) 

(Public, NASDAQ:TEVA)   Watch this stock   
Find more results forNASDAQ: TEVA
Nov 3, 2009
Q3 2009 Release
Nov 3, 2009
Q3 2009 Conference Call
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 18.37% 5.79%
Operating margin 21.21% 6.94%
EBITD margin - 11.34%
Return on average assets 7.98% 2.28%
Return on average equity 14.04% 4.23%
Employees 38,307 -

Address

5 Basel Street PO Box 3190
Petach Tikva, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9267472 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Transcripts - SeekingAlpha

Teva Pharmaceutical Industries Ltd (ADR) discussions

  View all discussions »

Description

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

Officers and directors

Eli Hurvitz
Chairman of the Board
Portrait Age: 77
Bio & Compensation - Reuters
Shlomo Yanai
Chief Executive Officer, President
Age: 57
Bio & Compensation - Reuters
Phillip Frost M.D.
Vice Chairman of the Board
Age: 72
Bio & Compensation - Reuters
Eyal Desheh
Chief Financial Officer
Age: 56
Bio & Compensation - Reuters
William S. Marth
President and Chief Executive Officer of Teva North America, President and CEO of Teva USA
Age: 54
Bio & Compensation - Reuters
Isaac Abravanel
Corporate Vice President - Human Resources
Age: 54
Bio & Compensation - Reuters
Chaim Hurvitz
Group Vice President - International
Age: 48
Bio & Compensation - Reuters
Moshe Manor
Group Vice President - Global Branded Products
Age: 53
Bio & Compensation - Reuters
Eli Shohet
Vice President - Central & Eastern Europe
Age: 51
Bio & Compensation - Reuters
Aharon Yaari
Group Vice President - Global API division
Age: 56
Bio & Compensation - Reuters